A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy.

BOUNCE: Brigatinib post definitive chemo-radiotherapy in patients with ALK-fusion non-small cell lung cancer

Trial Scheme

 BOUNCE   Trial Schema v1.1 20221216 ENG


Primary Endpoint: Progression-free survival (PFS) according to RECIST v1.1
Secondary Endpoints:

Overall survival

CNS-relapse-free survival

Pattern of disease progression

Toxicity according to CTCAE v5.0

Target Sample Size: 44 randomised patients (approximately 55 enrolled)
Protocol Release Date: 6 February 2024

Trial Organisation

Trial Chair:

Rafal Dziadziuszko, Gdansk, Poland
Trial Co-Chair:

Sanjay Popat, London, United Kingdom

Sponsor: ETOP IBCSG Partners Foundation
Coordinating Group: ETOP IBCSG Partners Foundation
Participating Groups: SLCGT
Participating Countries:   

France, Italy, Poland, Spain, and the United Kingdom


EU CT number: 2022-502467-38

clinicaltrials.gov: NCT05718297


Rico Hunkeler (Clinical Trial Manager)

This email address is being protected from spambots. You need JavaScript enabled to view it.


ETOP IBCSG Partners Foundation

Effingerstrasse 33

3008 Bern, Switzerland